Mirum Pharmaceuticals, Inc. (MIRM) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 618.07M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $618.07M | (m) | (m) |
| 2026-03-31 | (m) | $569.61M | (m) | (m) |
| 2025-12-31 | (m) | $521.31M | (m) | (m) |
| 2025-09-30 | (m) | $471.79M | (m) | (m) |
| 2025-06-30 | (m) | $429.16M | (m) | (m) |
| 2025-03-31 | (m) | $379.25M | (m) | (m) |
| 2024-12-31 | (m) | $336.89M | (m) | (m) |
| 2024-09-30 | (m) | $307.03M | (m) | (m) |
| 2024-06-30 | (m) | $264.38M | (m) | (m) |
| 2024-03-31 | (m) | $224.00M | (m) | (m) |
| 2023-12-31 | (m) | $186.37M | (m) | (m) |
| 2023-09-30 | (m) | $144.73M | (m) | (m) |
| 2023-06-30 | (m) | $115.78M | (m) | (m) |
| 2023-03-31 | (m) | $95.77M | (m) | (m) |
| 2022-12-31 | (m) | $77.06M | (m) | (m) |
| 2022-09-30 | (m) | $52.29M | (m) | (m) |
| 2022-06-30 | (m) | $38.51M | (m) | (m) |
| 2022-03-31 | (m) | $32.03M | (m) | (m) |
| 2021-12-31 | (m) | $19.14M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $0.00 | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |